Market Flux Event

FDA Misses PDUFA Deadline for Savara's Rare Lung Disease Drug, Sending Shares Down 21.7%

Read this in the Market Flux app

Savara Inc. disclosed on November 20 that the U.S. Food and Drug Administration will not meet its November 22, 2026 PDUFA target action date for the company's molgramostim inhalation solution Biologics License Application, which seeks approval to treat autoimmune pulmonary alveolar proteinosis, a rare and serious lung disease. The FDA communicated that its review of the BLA remains ongoing but provided no revised action date, leaving the timeline for a decision uncertain.

Shares of the Yardley, Pennsylvania-based clinical-stage biopharmaceutical company fell 21.7% in premarket trading following the announcement, reflecting investor concern over the open-ended delay and the absence of any new target date from the agency.

© AI-generated summary is provided by Market Flux

Sources

  1. Business WireSavara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
  2. OpenOutcrier$SVRA (-21.7% pre) FDA misses action deadline on Savara's rare lung disease drug application
  3. BioStocks$SVRA FDA Has Informed that it Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date. No Revised Action Date Communicated by the FDA
  4. NasdaqSavara Says FDA Likely To Miss Molgramostim Review Deadline
  5. Seeking AlphaSavara drops after FDA says it will not meet molgramostim BLA action date